(erythromycin 3%-benzoyl peroxide 5% topical gel)
For Dermatological Use Only – Not for Ophthalmic Use
Benzamycin® Pak contains erythromycin [(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-
xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione]. Erythromycin is a macrolide antibiotic produced from a strain of Saccharopolyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.
Benzamycin ® Pak is indicated for the topical treatment of acne vulgaris.
Media Articles Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Galderma receives FDA approval for new antibiotic-free treatment option for acne patients
Source: Dermatology News From Medical News Today [2015.07.20]
Galderma Laboratories, L.P. has announced that the U.S. Food and Drug Administration (FDA) approved antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.
Nanoparticles used to prevent inflammatory acne through slow-released nitric oxide
Source: Dermatology News From Medical News Today [2015.07.16]
GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology.
Acne Pictures Slideshow: Quick Cover-ups, Do's and Don'ts
Source: MedicineNet Acne Specialty [2015.06.26]
Title: Acne Pictures Slideshow: Quick Cover-ups, Do's and Don'ts
Created: 8/1/2012 12:00:00 AM
Last Editorial Review: 6/26/2015 12:00:00 AM
Could a Vitamin Play a Role in Acne Outbreaks?
Source: MedicineNet Acne Specialty [2015.06.25]
Title: Could a Vitamin Play a Role in Acne Outbreaks?
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM
Acne patients: 'substantial proportion' fail to collect prescribed treatment
Source: Compliance News From Medical News Today [2015.03.22]
Dermatologist-prescribed treatments are being left on pharmacy shelves by up to a quarter of people with acne, according to a new study.
Clinical Trials Related to Benzamycin (Erythromycin / Benzoyl Peroxide Topical)
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Page last updated: 2015-07-20